

**Title: Psychiatric symptoms and syndromes transcending diagnostic boundaries in Indian multiplex families: The cohort of ADBS study**

**Running title:** Transdiagnostic manifestations in multiplex families

**Article type:** Perspective

**Authors:**

Vanteemar S Sreeraj, DPM, DNB (Psychiatry), PDF (Clinical Neurosciences and therapeutics in Schizophrenia)

Bharath Holla, MD, PDF (Addiction Psychaitry)

Dhruva Ithal, MD

Ravi Kumar Nadella, MD

Jayant Mahadevan, MD, DM (Addiction Psychiatry)

Srinivas Balachander, MD, PDF (OCD)

Furkhan Ali, MD

Sweta Sheth, MD

Janardhanan C. Narayanaswamy, MD

Ganesan Venkatasubramanian, MD, PhD

John P. John, MD

Mathew Varghese, MD

Vivek Benegal, MD, DPM

Sanjeev Jain, MD

YC Janardhan Reddy, MD

ADBBS Consortium#,

Biju Viswanath\*, MD, PhD.

**Affiliations:** Department of Psychiatry, National Institute of Mental health and Neurosciences (NIMHANS), Bengaluru, India

**\*Corresponding Author:**

Dr. Biju Viswanath,

Associate Professor of Psychiatry,

National Institute of Mental Health and Neurosciences, Bangalore, India 560029

Phone: +91 80 2699 5791; Mob: +919480829594

Email: [bijuv1@gmail.com](mailto:bijuv1@gmail.com)

#Accelerator Program for Discovery in Brain disorders using Stem cells (ADBS) Consortium: Naren P. Rao<sup>1</sup>, Palanimuthu T. Sivakumar<sup>1</sup>, Arun Kandasamy<sup>1</sup>, Muralidharan Kesavan<sup>1</sup>, Urvakhsh Meherwan Mehta<sup>1</sup>, Odity Mukherjee<sup>2</sup>, Meera Purushottam<sup>1</sup>, Bhupesh Mehta<sup>1</sup>, Thennarasu Kandavel<sup>1</sup>, B. Binukumar<sup>1</sup>, Jitender Saini<sup>1</sup>, Deepak Jayarajan<sup>1</sup>, A. Shyamsundar<sup>1</sup>, Sydney Moirangthem<sup>1</sup>, K. G. Vijay Kumar<sup>1</sup>, Jagadisha Thirthalli<sup>1</sup>, Bangalore N. Gangadhar<sup>1</sup>, Pratima Murthy<sup>1</sup>, Mitradas M. Panicker<sup>3</sup>, Upinder S. Bhalla<sup>3</sup>, Sumantra Chattarji<sup>2,3</sup>, Padinjat Raghu<sup>3</sup> & Mahendra Rao<sup>2</sup>

1. National Institute of Mental Health and Neuro Sciences (NIMHANS)
2. Institute for Stem Cell Biology and Regenerative Medicine (InStem)
3. National Center for Biological Sciences (NCBS).

**Abstract:**

Accelerator program for discovery in brain disorders using stem cells (ADBS) is an ongoing longitudinal study investigating the neurobiological aspects of five psychiatric disorders (Alzheimer's dementia, bipolar disorder, obsessive-compulsive disorder, substance use disorder or schizophrenia) in India. The study uses several techniques (brain-imaging, psychophysics, neuropsychology, next-generation sequencing, cellular models), and in-depth clinical assessments in a longitudinal cohort from multiple-affected families. This article explores the frequency of manifestations of different psychiatric symptoms and syndromes in the participants and their relatives from the first wave of this study (August 2016 to October 2019). We screened 3,583 families and enrolled 481 families (1406 participants; 773 affected with any of the 5 disorders, and 633 relatives). The participants had a high familial prevalence with nearly a third of FDRs affected. Though similar disorders aggregated, the majority (61%) of the families had dissimilar diagnoses among members. Moreover, 15% of affected participants had two or more co-occurring syndromes. Diverse cross-cutting symptoms, unrestricted to the index syndrome, were observed in participants across diagnostic categories. The pattern and extent of co-occurrence validate the need for a transdiagnostic approach. The repository of biomaterials as well as digital datasets will serve as a valuable resource for the larger scientific community.

## Introduction

Psychiatric disorders are a significant cause of morbidity and ill health. A better understanding of the basic mechanisms of pathobiology that contribute to these syndromes is essential for improved interventions<sup>1</sup>. Recent findings, using diverse strategies ranging from epidemiology, and descriptive psychopathology, to pathophysiology and genetics, suggest that the diagnostic categories (of the various syndromes) may not be distinct and that transdiagnostic studies are thus necessary for brain-based disorders<sup>2-17</sup>. The transition in research from traditional categorical approaches to brain-based dimensional approaches has been proposed by the Research Domain Criteria (RDoC) project following suggestions by the National Institute of Mental Health<sup>18, 19</sup>. This approach is further validated by large-scale, cross-disorder genetic studies, that show a significant genetic overlap between multiple psychiatric disorders<sup>3, 20-23</sup>. Such overlaps have also been found in terms of brain markers in recent transdiagnostic studies<sup>8, 24</sup>. The presence of overlaps does not necessarily mean an absence of specific factors, though attempts to identify these have had equivocal success<sup>17</sup>.

One of the reasons for difficulty in finding disorder-specific factors is that the single-disorder, as well as cross-disorder, studies have generally not paid adequate attention to the familial risk of other disorders. The risk of psychiatric conditions is known to be transmitted in families, perhaps through a combination of both genetic and environmental factors. Individuals from families with multiple affected members could have a dense accumulation of the biological and environmental factors<sup>25</sup> that contribute to risk. The amount of overlap of symptoms and syndromes in the members of the multiplex families thus needs to be better documented and investigated.

Most of the large-scale cross-disorder efforts in this direction are situated in high-income countries in Europe and North America<sup>26</sup>. The Accelerator program for Discovery in Brain disorders using Stem cells (ADBS) is an effort to bridge this gap using a transdiagnostic longitudinal cohort of multiple-affected families in India<sup>27</sup>. Large family sizes and high levels of endogamy in India provides a unique and valuable source for family-based studies in understanding the pathogenesis of complex mental disorders<sup>28-31</sup>. We aimed at evaluating the frequency of occurrence of different symptoms and syndromes in relatives of those with severe mental illness. The major psychiatric disorders do not necessarily 'breed true', and it is often observed that index probands have a family history of different psychiatric illnesses<sup>27, 32-35</sup>. The current analysis thus also aimed at evaluating the aggregation patterns of different disorders in multiplex families.

### 1. Methods

This analysis draws on data from the ADBS project, an ongoing longitudinal collaborative by the National Institute of Mental Health and Neurosciences (NIMHANS), the National Centre for Biological Sciences (NCBS) and the Institute for Stem Cell Science and Regenerative Medicine (InStem), which began in August 2016<sup>27</sup>. Participants were identified from the health services of NIMHANS. Individuals with a

diagnosis of substance use disorder (SUD), bipolar disorder (BD), Alzheimer's dementia (AD), obsessive-compulsive disorder (OCD) or schizophrenia (SCZ) under clinical care at the hospital were screened for an additional presence of a first-degree relatives (FDR) with either the same or any of the other four disorders. A total of 3,583 patients (from August 2016 to October 2019) attending the adult psychiatry services and different specialty psychiatry clinics (Geriatric clinic/center for addiction medicine/Schizophrenia clinic/Obsessive-compulsive disorder clinic) of the NIMHANS were screened. The study population was selected from a combination of modal instance sampling (multiplex family), diversity sampling (representation of 5 different disorders) and convenience sampling (from a tertiary health care center) methods. Identified families with multiple affected individuals were invited to participate with as many members (affected as well as unaffected) from each family as possible. Written informed consent was obtained from each participant and the proposal was approved by the institutional ethics committee. A detailed pedigree was drawn and the family interview for genetic studies (FIGS) based screening for psychiatric disorders was carried out. This was performed by an independent interview of at least two informants by a trained mental health professional (psychiatrist/psychiatric social worker/clinical psychologist). All psychiatric diagnoses were corroborated by two trained psychiatrists with ascertainment using the Mini International Neuropsychiatric Interview (MINI)<sup>36</sup> and in accordance with DSM-IV-TR<sup>37</sup>.

### 1.1. Baseline characteristics of the participants

The biographic and clinical profile of the initial 1406 participants from 481 multiplex families is described in this paper. Diagnoses within the main DSM-IV category of SCZ and related disorders were subsumed under SCZ and both bipolar I & II disorders were considered as BD. Individuals who had met criteria more than one of the psychiatric diagnoses were grouped as "Complex severe mental illness (Complex SMI)". Schizoaffective disorder, bipolar type, was considered as Complex SMI and analyzed as individuals having phenotypes of both SCZ and BD. Dependence on any of the psychotropic substances in their lifetime, excluding nicotine, were considered as SUD. Some of the relatives who were found to have psychiatric disorders other than the five disorders under study were grouped as "other psychiatric disorders" and those without any axis-I psychiatric condition were regarded as "unaffected relatives".

DSM5 self-rated Level-1 cross-cutting symptom measure-adult<sup>38</sup> was used to elicit dimensional psychiatric symptom profile of the participants (n=1373; missing=33 which included 25 participants aged less than 18 years) in the past 2 weeks. It measures the frequency of the symptoms in the past two weeks and those symptoms crossing the threshold were counted as significant symptoms. The proportion of individuals with each significant symptom prompting clinical attention was calculated across each diagnostic category.

### 1.2. Clinical profile of the families

The identified families could be further defined as “families with similar disorders” (all affected individuals have the same syndrome) or “families with dissimilar disorders” (members may have any of the five disorders in the family) based on the FIGS assessment of FDR and second-degree relatives (SDR) of each participant in the study. The prevalence of psychiatric morbidities in FDRs and SDRs of the study participants from multiplex families was calculated with FIGS based on family history data.

As multiple members from a single-family are included as probands, the same relatives would be included independently multiple times in the series. For example., if two siblings participated in the study, their parents would be considered twice for the prevalence estimation. To overcome the unequal probabilities in the sample design, a complex sampling design statistic in IBM® SPSS® Statistic version 23.0 (IBM® corp,) was used for the analysis of prevalence rates. Each family was considered a cluster and the estimates were weighted for the number of participants from each family. A simple random sample design was assumed within the clusters for the standard error calculation with finite population correction<sup>39, 40</sup>.

Lifetime prevalence in relatives was calculated as the proportion of relatives who have ever had a psychiatric disorder at any time in their life up to the time of assessment. Similar to Weinberg's shorter method, relatives who were below the age at risk for developing psychiatric conditions (<13 years) were excluded from this calculation<sup>41</sup>. As individuals of all the age groups are potentially at risk for developing AD in their lifetime, we did not use the age correction for at-risk age and above-risk age. Due to the unavailability of data, niece/nephew and grandchildren were not considered in the SDRs.

The prevalence of each of the five disorders in the relatives was calculated separately<sup>42</sup>. Also, the transdiagnostic prevalence was calculated for the presence of any of the five diagnoses within the family. They were described across participant's diagnoses. Thereafter, the prevalence rates (P) and prevalence ratio (PR) of having similar and dissimilar diagnoses were calculated for each of the five diagnoses. An example formula for BD is shown below:

$P_{\text{Similar diagnosis for BD}} = [\text{total number of BD FDRs of BD participants} / \text{total number of FDRs of BD participants above 13 years of age}] \times 100.$

$P_{\text{Dissimilar diagnosis for BD}} = [\text{total number of FDRs with AD or OCD or SCZ or SUD of BD participants} / \text{total number of FDRs of BD patients above 13 years of age}] \times 100.$

$P_{\text{Similar diagnosis for BD among affected}} = P_{\text{Similar diagnosis for BD}} / (P_{\text{Similar diagnosis for BD}} + P_{\text{Dissimilar diagnosis for BD}})$

$P_{\text{Ratio}} = P_{\text{Similar diagnosis for BD}} / P_{\text{Dissimilar diagnosis for BD}}$

Similarly, P and PR were calculated for the psychiatric conditions from the extended relatives (consisting of both FDR+SDR).

## 2. Results

### 2.1. Psychiatric symptoms and syndromes in the participants

Among 1406 individuals, 773 (55%) had one of the five psychiatric diagnoses under the study (Table 1). From among this set, 114 (15%) had two or more of the five syndromes in their lifetime. The remaining 633 (45%) individuals who participated from these families did not have any of these five diagnoses. But, 82 (13%) had “other psychiatric disorders” (Table 1). From among all persons with a DSM-IV diagnosis (773+82=855), 206 (24%) had lifetime co-occurrence of two (or more) DSM-IV syndromes.

The sample was densely represented by participants from south-India, with around 12% of participants from other parts of India (Supplementary figure S1). A high socio-functional disruption was noted in terms of remaining single (unmarried/ separated) (38%) and unemployed (20%) with an average illness duration of more than a decade (14±12 years) in the affected participants (Demographic details in Supplementary Table S1).

DSM-5 cross-cutting symptom measure revealed that only a third (34%) of the sample had no psychiatric symptom above the clinical frequency threshold. While 20% had one symptom, four participants had ten out of thirteen clinically significant domain symptoms (for the entire range across each group see figure S2). Forty percent of the unaffected relatives had a minimum one significant psychiatric symptom. Overall, in the study participants, depressive symptoms (26%) were the most common reported symptom followed by somatic symptoms (24%), substance use (23%), anxiety (20%) and sleep (20%). Suicidal ideation was present in 11% of the individuals in the last two weeks. Dissociative symptoms (3%), mania (6%) and psychotic symptoms (8%) were cross-sectionally the least prevalent domains. Other symptoms like memory problems, anger problems, obsessive-compulsive symptoms, and personality dysfunction were detected in more than one-tenth of the individuals (Figure 1). Patients with SUD, OCD, and AD had respective symptom domains (87%, 91% & 87%, respectively) as the most prevalent. Depression was the most prevalent clinical symptom in the prior two-weeks in patients with BD (22%), SCZ (33%), complex SMI (43%) and other psychiatric disorders (41%) groups (Figure S2).

## 2.2. The pattern of aggregation of psychiatric diagnosis within the families

The 481 multiplex families in the study have a median of 3 (range: 1-14, mean-2.9, SD-1.3) individuals participating from each family. Families with differing syndromes in affected individuals were more frequent (61%, 295 families). In the other 186 families, all affected individuals had the same diagnosis. SUD families were the majority with 49% (92 families) of all families with similar disorders, and each of the remaining four diagnoses had only 10%-15% share (Figure 2a). The majority of participants with SUD (68%) were from families with similar diagnoses, but this proportion was lower in other diagnoses (AD-38%, OCD-39%, SCZ-27%, BD-25%) (Figure 2b).

The lifetime prevalence of psychiatric syndromes was calculated among relatives (SDRs=19,559, 14.18±5.45 per participant, FDRs=9,241, 6.7±3.18 per participant) of 1379 participants from 477 families. Though one another affected FDR was the minimum inclusion criteria, an average of 2.12 (±1.35) FDRs

and an additional 1.05 ( $\pm 1.66$ ) SDR of the affected participants had one of the five conditions. Twenty-seven individuals were excluded due to insufficient FIGS data. The overlapping relatives within the families are adjusted for double-counting using complex sample statistics, as described in the methods section. On estimating the prevalence, 33% (95% CI: 31%-35%) of FDRs and 23% (21%-24%) of extended relatives of the participants had any of the five diagnoses. This implies that every one in three FDR and one in the fifth SDR of a person from multiplex families was affected with any of the five disorders. A similar trend was observed in FDRs for all five disorders [SUD: 10% (CI:8%-11%), BD: 8% (6%-11%), SCZ: 8% (6%-9%), OCD: 5% (3%-6%) and AD: 2% (2%-3%)]. The same order of frequency was noted even after adding SDRs though prevalence was lesser than that in FDRs alone (Figure 2C,2D & Table 2).

The prevalence of affected FDRs was least for participants with AD at 20% (16%-23%) and highest for BD at 37% (28%-45%) (supplementary table S2). Affected participants had a higher prevalence of the same disorder in their relatives (11%-26% in FDRs, 9%-23% in extended relatives) than the other four disorders put together (6%-12% in FDRs, 4%-9% in SDRs). This suggests that similar diagnoses do aggregate in the multiplex families. However, the occurrence of other disorders was also quite significant. Nearly every third affected FDR of the participants with AD, SCZ, OCD, and BD had a different diagnosis (Table 2).

### 3. Discussion

Kessler et al.<sup>43</sup> observed that “*Although mental disorders are widespread, serious cases are concentrated among a relatively small proportion of cases with high comorbidity*”. The “serious cases” in this study were selected from a large tertiary psychiatric hospital after screening for the presence of a strong family history to achieve the project objectives<sup>27</sup>. The five disorders (SUD, BD, SCZ, OCD, and AD) opted in the project cause significant disability and impose a burden on the individuals, their families and the society. A high rate of unemployment and remaining single/separated highlights the social decline as a consequence of psychiatric disorders in these families.

The identified participants had a high familial risk, with nearly 1/3<sup>rd</sup> of FDRs affected. The majority of multiplex families had members with dissimilar diagnoses and not just the same diagnosis. A good proportion of affected participants had co-occurring syndromes over their lifetime. Diverse cross-cutting symptoms, not restricted to the index syndrome, are also observed in participants. Symptoms were observed in a significant proportion of apparently unaffected FDRs.

#### 3.1. Phenotypic diversity: symptom overlap across diagnostic groups

A vast amount of phenotypic diversity is observed within and across individuals. As much as 15% of the individuals with these five psychiatric disorders had co-occurrence of two or more of these syndromes,



during their course of illness. If we include any DSM-IV diagnosis, the number goes up to 24%. Even in those without a comorbid diagnosis, the subsyndromal psychiatric symptoms were found across nosological categories<sup>15</sup>. Overall one in every four participants having significant depressive symptoms and 10% having suicidality in the preceding two weeks echoes the severity of psychological problems in such families. Although most of the patients with varied diagnoses were on treatment and in different stages of recovery, the cross-sectional evaluation of psychiatric symptoms in the prior two weeks suggests the presence of a gamut of behavioral and psychological phenotypes. Symptoms transcending across traditional diagnostic boundaries highlight the need for a symptom-based approach<sup>44-48</sup> and a dimensional approach suggested by the RDoC<sup>19, 49</sup>.

### 3.2. Clinical status of “unaffected” FDRs

A significant proportion (12.4%) of FDRs who were included in the study for their at-risk status were found to have a diagnosable psychiatric diagnosis on structured clinical evaluation. Among the remaining relatives without any psychiatric morbidity, 39% had a psychiatric symptom crossing the threshold of clinical significance in the DSM-V cross-cutting symptoms measure. A higher proportion of symptoms and psychiatric syndromes in the apparently unaffected FDRs could indicate their higher biological vulnerability<sup>35</sup> or high psychosocial burden in caring for multiple relatives with SMI<sup>50-52</sup>. This further necessitates long-term follow up of such individuals to understand the biological and psychosocial interactions associated with the evolution of severe phenotypes, as envisaged in ADBS.

### 3.3. Familial aggregation pattern of psychiatric diagnoses

The ascertainment of higher familial risk in this sample is intended to identify ‘genetically enriched’ pedigrees. High familial risk in this sample was demonstrated by the presence of psychiatric disorders in nearly one-third of FDRs and nearly 22% of extended relatives of the participants. A recent national mental health survey (NMHS) in India indicates a lifetime prevalence of SUD (4.6%), BD (0.5%), OCD (0.8%), and SCZ (1.4%) in adult general population<sup>9</sup>. Maximum reported Indian prevalence of AD is 3.77% in those aged >55 years which equates to around 0.8% of the Indian adult population<sup>53</sup>. Thus, the combined prevalence rates of these disorders in the relatives of the participants were 3-4 times greater than that in the general population.

Increased familial risk is the major contributor to the propensity to develop severe mental illnesses<sup>54, 55</sup>. The majority of the families of the participants had different diagnoses among their members than a single specific syndrome (295 vs 196 families). Such diverse diagnoses within families are reported earlier<sup>15, 34, 56-59</sup>. Thus, these transdiagnostic multiplex families may represent a real-world scenario much better than syndrome specific multiplex families. However, similar diagnoses did tend to aggregate within the relatives. The prevalence of similar diagnoses was 1.5 to 4 times that of a dissimilar diagnosis, the highest being seen in SUD. The higher relative prevalence of similar diagnosis acknowledges, though

indistinct, the boundaries in existing diagnostic categorization. This indicates a need to design etiological studies within this transdiagnostic framework<sup>4, 59-62</sup>.

### 3.4. Implications

Transdiagnostic research is yielding novel insights into role of the neuronal markers<sup>8, 10, 12, 20, 24, 63</sup>, molecular<sup>7, 64, 65</sup>, genetic<sup>3, 5, 7, 22, 34, 54, 55</sup> as well as psychosocial factors<sup>13, 66</sup>. Pleiotropic genetic loci associated with multiple psychiatric conditions are being identified<sup>67</sup>. An understanding of mechanisms that are unique as well as shared across disorders considering interindividual and intrafamilial phenotypic diversity is thus necessary<sup>18, 19, 49</sup>. Consenting individuals from this transdiagnostic multiplex families undergo detailed assessment for developmental anomalies, temperament, personality, past psychosocial adversities, socioeconomic status, and the severity of psychopathology. Structural and functional magnetic resonance imaging (MRI), electroencephalography/evoked potential(EEG), functional near infra-red spectroscopy(fNIRS) and eye movement tracking are being done for these participants since August 2017<sup>27</sup>. A repository of induced pluripotent stem cells, lymphoblastoid cell lines and other biomaterials (serum, plasma, DNA) has been established and is being expanded. The bio-repository comprised of this “enriched” sample will be maximally representative of individuals with severe psychiatric disorders and those with very high susceptibility; and, thus, provide a great opportunity to answer several questions related to the neurobiology and pathogenesis of psychiatric disorders. This cohort is planned to undergo biennial assessments with detailed clinical, neuroimaging and neurophysiological tools, the second phase of which has begun in August 2019.

ADBS intends to make the raw de-identified data (clinical, MRI, EEG, fNIRS, eye tracking and DNA sequence data) and biological resources (plasma samples, genomic DNA and cell lines) generated from its research activities available to the wider scientific community. A data bank and bio-repository are being developed in the project. All raw data from clinical endophenotyping studies will be available for sharing with external investigators 12 months after the baseline data acquisition is completed. All cell lines generated by ADBS will be made available for sharing with external investigators, without the need to collaborate with an ADBS investigator, 12 months after the generation of cell lines has been completed from a single-family. Even before this embargo period, external investigators can embark on a formal collaboration with ADBS investigators to use the data and resources. The sharing of data and resources will follow due process with approval from the resource sharing and management boards. A full list of ADBS PIs and their contact details are available on the ADBS websites (<https://ncbs.res.in/adbs/home> & <http://adbsnimhans.org/>).

### 3.5. Limitations

Few limitations are to be acknowledged. The transdiagnostic approach is limited to the affected status of five specific psychiatric disorders. This a major step in using a transdiagnostic approach in understanding

the biological bases of severe mental disorders; but is inadequate to interrogate mechanisms of common syndromes of anxiety and depressive disorders<sup>14</sup>. The five syndromes become manifest from young adult life to late life (AD). A uniform age-at-risk of 13 years and above may not be equally representative of each of the syndromes. A non-probabilistic sampling method was applied for the efficient identification of highly vulnerable families. Hence, we need to acknowledge the possibility of selection bias and limitations in generalizing the estimates to the wider universe of multiplex families. The affected status of non-participating family members is ascertained by family history methods, and thus the knowledge of mildly affected members or those who chose not to disclose their family history may have been missed. However, family history was obtained from at least two FDRs that would partially compensate for any possible reporting bias. An unbiased ascertainment for non-occurrence is not possible in relatives given the persistent risk for future occurrence. Nevertheless, the obtained estimates are conservative and the actual familial risk might be much higher than reported.

### 3.6. Conclusions

The ADBS study is congregating participants from extremely dense families with five psychiatric disorders. Most of these families have their members unrestricted to a single-diagnosis with a high prevalence of co-occurrence of syndromes in the affected individuals. In addition, a significant proportion of participants, across all diagnostic groups (including the unaffected relatives) have subsyndromal psychiatric symptoms of diverse domains. However, similar syndromes aggregate within the families and specific symptoms aggregate within individuals with particular disorders. This sample would thus be helpful in elucidating the pathogenetic mechanisms that are specific and shared across disorders.

### **Funding acknowledgement**

This research is funded by the Accelerator program for discovery in brain disorders using stem cells (ADBS) (funded by the Department of Biotechnology, Government of India (BT/PR17316/MED/31/326/2015)).

### **Conflict of interest**

The authors declare no conflict of interest

## References

1. Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. *Lancet Psychiatry* 2016; **3**(2): 171-178.
2. International Obsessive Compulsive Disorder Foundation Genetics C, Studies OCDCGA. Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. *Mol Psychiatry* 2018; **23**(5): 1181-1188.
3. Maier R, Moser G, Chen GB, Ripke S, Cross-Disorder Working Group of the Psychiatric Genomics C, Coryell W *et al*. Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorder. *Am J Hum Genet* 2015; **96**(2): 283-294.
4. Mitropoulos GB. The DSM-ICD diagnostic approach as an essential bridge between the patient and the "big data". *Psychiatriki* 2018; **29**(3): 249-256.
5. Pouget JG, Schizophrenia Working Group of the Psychiatric Genomics C, Han B, Wu Y, Mignot E, Ollila HM *et al*. Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk. *Hum Mol Genet* 2019.
6. Docherty AR, Moscati AA, Fanous AH. Cross-Disorder Psychiatric Genomics. *Curr Behav Neurosci Rep* 2016; **3**(3): 256-263.
7. Yuan N, Chen Y, Xia Y, Dai J, Liu C. Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses. *Transl Psychiatry* 2019; **9**(1): 233.
8. Wang S, Gong G, Zhong S, Duan J, Yin Z, Chang M *et al*. Neurobiological commonalities and distinctions among 3 major psychiatric disorders: a graph theoretical analysis of the structural connectome. *J Psychiatry Neurosci* 2019; **44**(5): 1-8.
9. Gururaj G, Varghese M, Benegal V, N R, K P, Singh L *et al*. *National Mental Health Survey of India, 2015-16: Prevalence, patterns and outcomes*. National Institute of Mental Health and Neuro Sciences, NIMHANS Publication: Bengaluru, 2016.
10. Janiri D, Moser DA, Doucet GE, Luber MJ, Rasgon A, Lee WH *et al*. Shared Neural Phenotypes for Mood and Anxiety Disorders: A Meta-analysis of 226 Task-Related Functional Imaging Studies. *JAMA Psychiatry* 2019: 1-8.
11. Mitelman SA. Transdiagnostic neuroimaging in psychiatry: A review. *Psychiatry Res* 2019; **277**: 23-38.
12. Romanowska S, MacQueen G, Goldstein BI, Wang J, Kennedy SH, Bray S *et al*. Neurocognitive deficits in a transdiagnostic clinical staging model. *Psychiatry Res* 2018; **270**: 1137-1142.

13. Albott CS, Forbes MK, Anker JJ. Association of Childhood Adversity With Differential Susceptibility of Transdiagnostic Psychopathology to Environmental Stress in Adulthood. *JAMA Netw Open* 2018; **1**(7): e185354.
14. Fusar-Poli P, Solmi M, Brondino N, Davies C, Chae C, Politi P *et al.* Transdiagnostic psychiatry: a systematic review. *World Psychiatry* 2019; **18**(2): 192-207.
15. First MB, Rebello TJ, Keeley JW, Bhargava R, Dai Y, Kulygina M *et al.* Do mental health professionals use diagnostic classifications the way we think they do? A global survey. *World Psychiatry* 2018; **17**(2): 187-195.
16. van Os J, Reininghaus U. Psychosis as a transdiagnostic and extended phenotype in the general population. *World Psychiatry* 2016; **15**(2): 118-124.
17. Caspi A, Moffitt TE. All for One and One for All: Mental Disorders in One Dimension. *Am J Psychiatry* 2018; **175**(9): 831-844.
18. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K *et al.* Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. *Am J Psychiatry* 2010; **167**(7): 748-751.
19. Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. *World Psychiatry* 2014; **13**(1): 28-35.
20. Schork AJ, Brown TT, Hagler DJ, Thompson WK, Chen CH, Dale AM *et al.* Polygenic risk for psychiatric disorders correlates with executive function in typical development. *Genes Brain Behav* 2019; **18**(4): e12480.
21. Brainstorm C, Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J *et al.* Analysis of shared heritability in common disorders of the brain. *Science* 2018; **360**(6395).
22. Jia X, Yang Y, Chen Y, Cheng Z, Du Y, Xia Z *et al.* Multivariate analysis of genome-wide data to identify potential pleiotropic genes for five major psychiatric disorders using MetaCCA. *J Affect Disord* 2019; **242**: 234-243.
23. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric Genomics C *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* 2015; **47**(3): 291-295.
24. Gong Q, Scarpazza C, Dai J, He M, Xu X, Shi Y *et al.* A transdiagnostic neuroanatomical signature of psychiatric illness. *Neuropsychopharmacology* 2019; **44**(5): 869-875.

25. Okayama T, Hashiguchi Y, Kikuyama H, Yoneda H, Kanazawa T. Next-generation sequencing analysis of multiplex families with atypical psychosis. *Transl Psychiatry* 2018; **8**(1): 221.
26. Stevenson A, Akena D, Stroud RE, Atwoli L, Campbell MM, Chibnik LB *et al.* Neuropsychiatric Genetics of African Populations-Psychosis (NeuroGAP-Psychosis): a case-control study protocol and GWAS in Ethiopia, Kenya, South Africa and Uganda. *BMJ Open* 2019; **9**(2): e025469.
27. Viswanath B, Rao NP, Narayanaswamy JC, Sivakumar PT, Kandasamy A, Kesavan M *et al.* Discovery biology of neuropsychiatric syndromes (DBNS): a center for integrating clinical medicine and basic science. *BMC Psychiatry* 2018; **18**(1): 106.
28. Konkel L. Racial and Ethnic Disparities in Research Studies: The Challenge of Creating More Diverse Cohorts. *Environ Health Perspect* 2015; **123**(12): A297-302.
29. Arcaya MC, Arcaya AL, Subramanian SV. Inequalities in health: definitions, concepts, and theories. *Glob Health Action* 2015; **8**: 27106.
30. Indian Genome Variation C. Genetic landscape of the people of India: a canvas for disease gene exploration. *J Genet* 2008; **87**(1): 3-20.
31. Basu A, Mukherjee N, Roy S, Sengupta S, Banerjee S, Chakraborty M *et al.* Ethnic India: a genomic view, with special reference to peopling and structure. *Genome Res* 2003; **13**(10): 2277-2290.
32. Kendler KS, Prescott CA, Myers J, Neale MC. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. *Arch Gen Psychiatry* 2003; **60**(9): 929-937.
33. Post RM, Altshuler LL, Kupka R, McElroy SL, Frye MA, Rowe M *et al.* Multigenerational transmission of liability to psychiatric illness in offspring of parents with bipolar disorder. *Bipolar Disord* 2018.
34. Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF *et al.* Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. *Lancet* 2009; **373**(9659): 234-239.
35. Chou IJ, Kuo CF, Huang YS, Grainge MJ, Valdes AM, See LC *et al.* Familial Aggregation and Heritability of Schizophrenia and Co-aggregation of Psychiatric Illnesses in Affected Families. *Schizophr Bull* 2017; **43**(5): 1070-1078.
36. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E *et al.* The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* 1998; **59 Suppl 20**: 22-33;quiz 34-57.

37. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders (4th ed., Text Revision)*: Washington, DC, 2000.
38. Narrow WE, Clarke DE, Kuramoto SJ, Kraemer HC, Kupfer DJ, Greiner L *et al.* DSM-5 field trials in the United States and Canada, Part III: development and reliability testing of a cross-cutting symptom assessment for DSM-5. *Am J Psychiatry* 2013; **170**(1): 71-82.
39. Hahs-Vaughn DL, McWayne CM, Bulotsky-Shearer RJ, Wen X, Faria AM. Methodological considerations in using complex survey data: an applied example with the Head Start Family and Child Experiences Survey. *Eval Rev* 2011; **35**(3): 269-303.
40. Lin DY, Tao R, Kalsbeek WD, Zeng D, Gonzalez F, 2nd, Fernandez-Rhodes L *et al.* Genetic association analysis under complex survey sampling: the Hispanic Community Health Study/Study of Latinos. *Am J Hum Genet* 2014; **95**(6): 675-688.
41. Chase GA, Kramer M. The abridged census method as an estimator of lifetime risk. *Psychol Med* 1986; **16**(4): 865-871.
42. Cardno AM, P. *Quantitative genetics*. Oxford University Press: Oxford, England, 2002.
43. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005; **62**(6): 617-627.
44. Schmidt U. A plea for symptom-based research in psychiatry. *Eur J Psychotraumatol* 2015; **6**: 27660.
45. Krueger RF, Kotov R, Watson D, Forbes MK, Eaton NR, Ruggero CJ *et al.* Progress in achieving quantitative classification of psychopathology. *World Psychiatry* 2018; **17**(3): 282-293.
46. Parnas J. Differential diagnosis and current polythetic classification. *World Psychiatry* 2015; **14**(3): 284-287.
47. Kotov R, Krueger RF, Watson D, Achenbach TM, Althoff RR, Bagby RM *et al.* The Hierarchical Taxonomy of Psychopathology (HiTOP): A dimensional alternative to traditional nosologies. *J Abnorm Psychol* 2017; **126**(4): 454-477.
48. Reininghaus U, Bohnke JR, Chavez-Baldini U, Gibbons R, Ivleva E, Clementz BA *et al.* Transdiagnostic dimensions of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). *World Psychiatry* 2019; **18**(1): 67-76.
49. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. *BMC Med* 2013; **11**: 126.

50. Koschorke M, Padmavati R, Kumar S, Cohen A, Weiss HA, Chatterjee S *et al.* Experiences of stigma and discrimination faced by family caregivers of people with schizophrenia in India. *Soc Sci Med* 2017; **178**: 66-77.
51. Viana MC, Gruber MJ, Shahly V, Alhamzawi A, Alonso J, Andrade LH *et al.* Family burden related to mental and physical disorders in the world: results from the WHO World Mental Health (WMH) surveys. *Braz J Psychiatry* 2013; **35**(2): 115-125.
52. Murthy RS. Family interventions and empowerment as an approach to enhance mental health resources in developing countries. *World Psychiatry* 2003; **2**(1): 35-37.
53. Mathuranath PS, Cherian PJ, Mathew R, Kumar S, George A, Alexander A *et al.* Dementia in Kerala, South India: prevalence and influence of age, education and gender. *Int J Geriatr Psychiatry* 2010; **25**(3): 290-297.
54. Sandstrom A, Sahiti Q, Pavlova B, Uher R. Offspring of parents with schizophrenia, bipolar disorder, and depression: a review of familial high-risk and molecular genetics studies. *Psychiatr Genet* 2019; **29**(5): 160-169.
55. Pettersson E, Lichtenstein P, Larsson H, Song J, Attention Deficit/Hyperactivity Disorder Working Group of the iPsych-Broad-Pgc Consortium ASDWGoti-B-PGCCBDWG, Tourette Syndrome Working Group of the Pgc SCSUDWGotPGC *et al.* Genetic influences on eight psychiatric disorders based on family data of 4 408 646 full and half-siblings, and genetic data of 333 748 cases and controls. *Psychol Med* 2019; **49**(7): 1166-1173.
56. Viswanath B, Narayanaswamy JC, Cherian AV, Reddy YC, Math SB. Is familial obsessive-compulsive disorder different from sporadic obsessive-compulsive disorder? A comparison of clinical characteristics, comorbidity and treatment response. *Psychopathology* 2011; **44**(2): 83-89.
57. Maier W. Genetic epidemiology of psychiatric disorders. *Eur Arch Psychiatry Clin Neurosci* 1993; **243**(3-4): 119-120.
58. Smoller JW, Finn CT. Family, twin, and adoption studies of bipolar disorder. *Am J Med Genet C Semin Med Genet* 2003; **123C**(1): 48-58.
59. Cheng CM, Chang WH, Chen MH, Tsai CF, Su TP, Li CT *et al.* Co-aggregation of major psychiatric disorders in individuals with first-degree relatives with schizophrenia: a nationwide population-based study. *Mol Psychiatry* 2018; **23**(8): 1756-1763.
60. First MB. Preserving the clinician-researcher interface in the age of RDoC: the continuing need for DSM-5/ICD-11 characterization of study populations. *World Psychiatry* 2014; **13**(1): 53-54.



61. Maj M. Why the clinical utility of diagnostic categories in psychiatry is intrinsically limited and how we can use new approaches to complement them. *World Psychiatry* 2018; **17**(2): 121-122.
62. Kendler KS. Classification of psychopathology: conceptual and historical background. *World Psychiatry* 2018; **17**(3): 241-242.
63. de Lange SC, Scholtens LH, Alzheimer's Disease Neuroimaging I, van den Berg LH, Boks MP, Bozzali M *et al.* Shared vulnerability for connectome alterations across psychiatric and neurological brain disorders. *Nat Hum Behav* 2019; **3**(9): 988-998.
64. Jauhar S, Nour MM, Veronese M, Rogdaki M, Bonoldi I, Azis M *et al.* A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia. *JAMA Psychiatry* 2017; **74**(12): 1206-1213.
65. Pinto JV, Moulin TC, Amaral OB. On the transdiagnostic nature of peripheral biomarkers in major psychiatric disorders: A systematic review. *Neurosci Biobehav Rev* 2017; **83**: 97-108.
66. Belhadj Kouider E, Petermann F. [Common Risk Factors of Depressive and Anxiety Symptomatology in Childhood and Adolescence: A Systematic Review from Transdiagnostic Perspectives]. *Fortschr Neurol Psychiatr* 2015; **83**(6): 321-333.
67. Cross-Disorder Group of the Psychiatric Genomics Consortium. Electronic address pmhe, Cross-Disorder Group of the Psychiatric Genomics C. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. *Cell* 2019; **179**(7): 1469-1482 e1411.

Figure legends:

**Figure 1: Point Prevalence of psychiatric symptoms in participants across diagnostic categories as measured by DSM5 level-1 cross-cutting measure**

Legend: various domains of psychiatric symptom crossing the threshold for clinical significance are observed in participants across all diagnostic categories. A significant proportion of the apparently unaffected participants also have different sub-syndromal clinical symptoms. This indicates the phenotypic diversity within the clinical categories.

SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive-Compulsive disorder; SCZ- Schizophrenia; AD- Alzheimer's Dementia; cSMI- Complex Severe Mental Illness, Other PsyD- Other Psychiatric Disorders.

**Figure 2: Frequency of occurrence of psychiatric syndromes in multiplex families**

(a) The frequency of families with multiple affected members with similar and dissimilar diagnoses are depicted. Most of the families had more than one diagnostic phenotype (dissimilar diagnoses). Half of all the families with one type of diagnosis consisted of only SUD.

(b) Participants in all different diagnostic categories had different proportions of families with more than one diagnostic phenotype (dissimilar diagnoses). Participants of all diagnostic categories, except for SUD, hailed from families with multiple diagnostic phenotypes. (c)

Prevalence of any the five disorders is around 4 times higher in the first-degree relatives and 3 times higher in extended relatives (combined first- and second-degree relatives) of the study participants compared to the general population prevalence. \*Transdiagnostic prevalence in the general population is calculated by the sum of the prevalence rates of all five disorders in the general population. (d) Prevalence of BPAD in FDRs of the participant from the multiplex family was nearly 17 times, schizophrenia and OCD-6 times, AD-3 times and SUD-2 times higher than that of the general population. Similarly, extended relatives had 2-10 times higher prevalence (2% with AD, 3% with OCD, 5% with BPAD and SCZ, and 8% with SUD) of these disorders in comparison to lifetime prevalence in general population.

Transdiagnostic- Overall prevalence of any of the five disorders, SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive-Compulsive disorder; AD- Alzheimer's Dementia; Complex SMI- Complex Severe Mental Illness; Others- Other psychiatric disorders, Indian Gen.Pop. - Indian general Population prevalence (based on National mental health survey, Gururaj et al., 2016 and Mathuranath et al., 2010).

**Figure S1: Geographical distribution of the study participants**

The sample has a higher representation of the population from 5 southern states of India, primarily due to the proximity of the study site.

Figure S2: 100% stacked column of distribution of psychiatric symptoms counts in participants across diagnostic categories as measured by DSM5 level-1 cross-cutting measure.

Each stack represents the number of symptom domains screened positive in DSM5 cross-cutting symptom measure. Less than 30% of the study participants have no clinically significant symptom. But nearly 50% have 2 or more domains of symptoms in the last 2 weeks displaying the intra-individual phenotypic diversity.

SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive Compulsive disorder; AD- Alzheimer's Dementia; Complex SMI- Complex Severe Mental Illness.

Table 1: Diagnostic description of participants

	Number of individuals	Percentage
<b>Total Participants*</b>	<b>1406</b>	
<b>Affected (with any of 5 disorder) Participants</b>	<b>773</b>	<b>100.00%</b>
SUD	165	21.34%
BD	151	19.53%
Schizophrenia	150	19.41%
OCD	117	15.14%
AD	76	9.83%
Total Complex SMI	114	14.75%
<b>Complex SMI</b>		
OCD + Schizophrenia	27	23.68%
BD + SUD	22	19.3%
Schizophrenia + SUD	20	14.91%
SAD	17	14.91%
BD + OCD	12	10.53%
AD + SUD	6	5.26%
BD + OCD + SUD	2	1.75%
OCD + SAD	2	1.75%
OCD + SUD	2	1.75%
SAD + SUD	2	1.75%
AD + BD	1	0.88%
AD + Schizophrenia	1	0.88%
<b>Participating relatives of affected individuals (without any of the 5 disorder)</b>	<b>633</b>	<b>100.00%</b>
<b>No Psychiatric disorder (includes Nicotine dependence)</b>	<b>551</b>	<b>87.05%</b>
<b>Other psychiatric disorders</b>	<b>82</b>	<b>12.95%</b>

<b>Other Psychiatric disorders</b>		
RDD	16	19.51%
Depression	14	17.07%
Alcohol Abuse	10	12.2%
Dysthymia	10	12.2%
Generalized Anxiety Disorder	10	12.2%
Adjustment Disorder	6	7.32%
Agoraphobia	3	3.66%
Panic Disorder	3	3.66%
ADHD	2	2.44%
Generalized Anxiety Disorder + Alcohol Abuse + OCPD	1	1.22%
Depression + Alcohol Abuse	1	1.22%
Depression + Dysthymia	1	1.22%
Dissociation	1	1.22%
Dysthymia + Anxiety	1	1.22%
Mild Cognitive Impairment	1	1.22%
Primary Insomnia	1	1.22%
Social Phobia	1	1.22%


SUD- Substance use disorder; BD- Bipolar Disorder; OCD- Obsessive compulsive disorder; AD- Alzheimer's dementia; SMI- Severe mental illness; SAD- Schizoaffective disorder; ADHD- Attention Deficit Hyperactivity Disorder; RDD – Recurrent Depressive Disorder; Depression – Major Depressive Disorder, Single episode; OCPD – Obsessive Compulsive Personality Disorder.

Table 2: Prevalence rates of similar and dissimilar psychiatric disorders and prevalence ratios across diagnostic categories

	FDRs					FDR+SDRs				
	P <sup>Similar</sup> diagnosis	P <sup>Dissimilar</sup> diagnosis	P <sup>Similar</sup> diagnosis among affected	P <sup>Dissimilar</sup> diagnosis among affected	PR	P <sup>Similar</sup> diagnosis	P <sup>Dissimilar</sup> diagnosis	P <sup>Similar</sup> diagnosis among affected	P <sup>Dissimilar</sup> diagnosis among affected	PR
<b>SUD</b>	25.91%	6.42%	0.80	0.20	4.04	22.89%	3.85%	0.86	0.14	5.94
<b>BD</b>	24.72%	12.03%	0.67	0.33	2.05	13.01%	8.63%	0.60	0.40	1.51
<b>Schizophrenia</b>	20.13%	11.83%	0.63	0.37	1.70	9.35%	7.33%	0.56	0.44	1.28
<b>OCD</b>	20.73%	10.71%	0.66	0.34	1.94	10.24%	8.76%	0.54	0.46	1.17
<b>AD</b>	11.41%	8.24%	0.58	0.42	1.38	10.60%	7.31%	0.59	0.41	1.45

SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive Compulsive disorder; AD- Alzheimer’s Dementia;  
Complex SMI- Complex Severe Mental Illness.


Figure 1: Point Prevalence of psychiatric symptoms in participants across diagnostic categories as measured by DSM5 level-1 cross-cutting measure




various domains of psychiatric symptom crossing the threshold for clinical significance are observed in participants across all diagnostic categories. A significant proportion of the apparently unaffected participants also have different sub-syndromal clinical symptoms. This indicates the phenotypic diversity within the clinical categories.

SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive-Compulsive disorder; SCZ- Schizophrenia; AD- Alzheimer’s Dementia; cSMI- Complex Severe Mental Illness, Other PsyD- Other Psychiatric Disorders.


**Figure 2:** Frequency of occurrence of psychiatric syndromes in multiplex families




**(a)**



**(b)**



**(c)**



**(d)**



(a) The frequency of families with multiple affected members with similar and dissimilar diagnoses are depicted. Most of the families had more than one diagnostic phenotype (dissimilar diagnoses). Half of all the families with one type of diagnosis consisted of only SUD. (b) Participants in all different diagnostic categories had different proportions of families with more than one diagnostic phenotype (dissimilar diagnoses). Participants of all diagnostic categories, except for SUD, hailed from families with multiple diagnostic phenotypes. (c) Prevalence of any the five disorders is around 4 times higher in the first-degree relatives and 3 times higher in extended relatives (combined first- and second-degree relatives) of the study participants compared to the general population prevalence. \*Transdiagnostic prevalence in the general population is calculated by the sum of the prevalence rates of all five disorders in the general population. (d) Prevalence of BPAD in FDRs of the participant from the multiplex family was nearly 17 times, schizophrenia and OCD-6 times, AD-3 times and SUD-2 times higher than that of the general population. Similarly, extended relatives had 2-10 times higher prevalence (2% with AD, 3% with OCD, 5% with BPAD and SCZ, and 8% with SUD) of these disorders in comparison to lifetime prevalence in general population.

Transdiagnostic- Overall prevalence of any of the five disorders, SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive-Compulsive disorder; AD- Alzheimer's Dementia; Complex SMI- Complex Severe Mental Illness; Others- Other psychiatric disorders, Indian Gen.Pop. - Indian general Population prevalence (based on National mental health survey, Gururaj et al., 2016 and Mathuranath et al., 2010).

Table S1: Baseline characteristics (continuous variables) of participants across different diagnostic categories<sup>a</sup>

		SUD (n=165)	BD (n=151)	AD (n=76)	OCD (n=117)	SCZ (n=150)	COMPLE X SMI (n=114)	OTHER DISORDER S (n=82)	UNAFFECTE D RELATIVES (n=551)	TOTAL (n=1406)
		mean (SD)	mean (SD)	mean (SD)	mean (SD)	mean (SD)	mean (SD)	mean (SD)	mean (SD)	mean (SD)
Age	(in years)	43.07 (12.57)	39.79 (13.48)	67.66 (9.63)	36.01 (14.53)	40.91 (13.32)	40.5 (14.1)	42.99 (15.47)	42.17 (15.35)	42.66 (15.5)
Education	(in years)	7.69 (4.76)	8.87 (5.77)	7.93 (5.67)	12.44 (4.27)	8.69 (4.76)	10.52 (4.61)	10.01 (5.38)	10.52 (5.07)	9.81 (5.2)
Age at Onset	(in years)	27.32 (10.23)	23.69 (9.93)	64.8 (9.52)	22.21 (10.66)	27.19 (9.34)	25.36 (11.89)	-	-	29.33 (15.89)
Duration of Illness	(in years)	15.95 (12.04)	16.31 (11.91)	2.75 (1.82)	13.75 (11.46)	13.92 (11.58)	15.48 (10.93)	-	-	13.77 (11.79)
		n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Sex	Male	154 (93.33%)	67 (44.37%)	34 (44.74%)	65 (55.56%)	65 (43.33%)	90 (78.95%)	31 (37.8%)	294 (53.36%)	800 (56.9%)
	Female	11 (6.67%)	84 (55.63%)	42 (55.26%)	52 (44.44%)	85 (56.67%)	24 (21.05%)	51 (62.2%)	257 (46.64%)	606 (43.1%)
Habitat	Rural	54 (32.93%)	68 (46.26%)	39 (51.32%)	40 (34.48%)	79 (54.11%)	43 (38.39%)	31 (37.8%)	205 (37.61%)	559 (40.27%)
	Urban	110 (67.07%)	79 (53.74%)	37 (48.68%)	76 (65.52%)	67 (45.89%)	69 (61.61%)	51 (62.2%)	340 (62.39%)	829 (59.73%)
Marital Status	Divorced or separated	4 (2.44%)	4 (2.74%)	(0%)	3 (2.59%)	15 (10%)	2 (1.77%)	1 (1.23%)	9 (1.64%)	38 (2.72%)
	Living as couple	(0%)	(0%)	(0%)	(0%)	(0%)	(0%)	(0%)	1 (0.18%)	1 (0.07%)
	Married	124 (75.61%)	87 (59.59%)	68 (89.47%)	62 (53.45%)	78 (52%)	60 (53.1%)	56 (69.14%)	405 (73.64%)	940 (67.34%)
	Unmarried	33 (20.12%)	49 (33.56%)	(0%)	50 (43.1%)	53 (35.33%)	50 (44.25%)	17 (20.99%)	118 (21.45%)	370 (26.5%)
	Widowed	3 (1.83%)	6 (4.11%)	8 (10.53%)	1 (0.86%)	4 (2.67%)	1 (0.88%)	7 (8.64%)	17 (3.09%)	47 (3.37%)
Occupation	Government employee	10 (6.1%)	5 (3.38%)	4 (5.26%)	8 (6.96%)	3 (2.01%)	3 (2.65%)	4 (4.88%)	41 (7.5%)	78 (5.6%)
	Homemaker	4 (2.44%)	47 (31.76%)	19 (25%)	33 (28.7%)	47 (31.54%)	13 (11.5%)	26 (31.71%)	113 (20.66%)	302 (21.66%)

Non-government employee	39 (23.78%)	28 (18.92%)	1 (1.32%)	19 (16.52%)	20 (13.42%)	19 (16.81%)	20 (24.39%)	134 (24.5%)	280 (20.09%)
Non-paid job	(0%)	(0%)	(0%)	(0%)	1 (0.67%)	(0%)	(0%)	1 (0.18%)	2 (0.14%)
Refused	(0%)	(0%)	(0%)	(0%)	1 (0.67%)	(0%)	(0%)	(0%)	1 (0.07%)
Retired	3 (1.83%)	1 (0.68%)	18 (23.68%)	2 (1.74%)	3 (2.01%)	4 (3.54%)	4 (4.88%)	28 (5.12%)	63 (4.52%)
Self-employed	94 (57.32%)	38 (25.68%)	9 (11.84%)	12 (10.43%)	21 (14.09%)	32 (28.32%)	18 (21.95%)	166 (30.35%)	390 (27.98%)
student	2 (1.22%)	12 (8.11%)	(0%)	26 (22.61%)	8 (5.37%)	6 (5.31%)	6 (7.32%)	50 (9.14%)	110 (7.89%)
Unemployed (able to work)	9 (5.49%)	14 (9.46%)	(0%)	9 (7.83%)	23 (15.44%)	18 (15.93%)	2 (2.44%)	11 (2.01%)	86 (6.17%)
Unemployed (unable to work)	3 (1.83%)	3 (2.03%)	25 (32.89%)	6 (5.22%)	22 (14.77%)	18 (15.93%)	2 (2.44%)	3 (0.55%)	82 (5.88%)

<sup>a</sup> The largest number of subjects available for each study group are presented. The proportion of missing data ranged from 0.71% to 1.28% for various sociodemographic factors.


SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive Compulsive disorder; SCZ- Schizophrenia; AD- Alzheimer's Dementia; Complex SMI- Complex Severe Mental Illness.

Table S2: Prevalence rates of the five psychiatric disorders in the FDRs as well as FDRs and SDRs of individuals from multiplex families across diagnostic categories

Diagnosis in Participants	P <sub>SUD</sub>		P <sub>BD</sub>		P <sub>AD</sub>		P <sub>OCD</sub>		P <sub>Schizophrenia</sub>		P <sub>Transdiagnosis</sub>	
	FDR	Extended Relatives	FDR	Extended Relatives	FDR	Extended Relatives	FDR	Extended Relatives	FDR	Extended Relatives	FDR	Extended Relatives
<b>SUD</b>	25.91%	22.89%	0.56%	0.56%	3.15%	1.88%	1.56%	0.85%	0.65%	0.56%	32.33%	26.75%
<b>BD</b>	5.00%	4.20%	13.01%	13.01%	5.54%	3.42%	1.49%	0.92%	0.00%	0.10%	36.75%	21.64%
<b>Schizophrenia</b>	6.27%	4.62%	1.90%	1.92%	20.13%	9.35%	1.68%	0.73%	0.19%	0.08%	31.95%	16.68%
<b>OCD</b>	4.15%	4.54%	1.80%	1.63%	3.80%	2.17%	20.73%	10.24%	0.30%	0.26%	31.44%	18.99%
<b>AD</b>	4.80%	4.22%	1.00%	1.00%	1.68%	1.57%	0.61%	0.52%	11.41%	10.60%	19.66%	17.90%
<b>Complex SMI</b>	13.68%	10.49%	5.36%	5.89%	4.75%	3.29%	6.76%	3.41%	1.77%	1.51%	33.42%	24.06%
<b>Other Psychiatric Disorder</b>	10.29%	8.21%	5.95%	5.21%	9.13%	4.86%	4.78%	2.34%	1.00%	0.58%	35.77%	21.94%
<b>Unaffected</b>	9.14%	8.78%	5.26%	5.21%	8.21%	5.35%	4.89%	2.69%	3.10%	3.09%	33.35%	25.17%
<b>Total</b>	9.69%	8.57%	5.14%	5.09%	7.66%	4.64%	4.63%	2.59%	2.31%	1.83%	32.72%	22.76%


P-Prevalence; SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive Compulsive disorder; AD- Alzheimer's Dementia; Complex SMI- Complex Severe Mental Illness.

Figure S1: Geographical distribution of the study participants



The sample has a higher representation of the population from 5 southern states of India, primarily due to the proximity of the study site.

Figure S2: 100% stacked column of distribution of psychiatric symptoms counts in participants across diagnostic categories as measured by DSM5 level-1 cross-cutting measure.



Each stack represents the number of symptom domains screened positive in DSM5 cross-cutting symptom measure. Less than 30% of the study participants have no clinically significant symptom. But nearly 50% have 2 or more domains of symptoms in the last 2 weeks displaying the intra-individual phenotypic diversity.

SUD- Substance use disorder; BPAD- Bipolar Affective disorder, OCD- Obsessive Compulsive disorder; AD- Alzheimer’s Dementia; Complex SMI- Complex Severe Mental Illness.